Citations

Clear

4 citation(s) found for "Sobhy, Ahmed".

Left Atrial Appendage Occlusion vs Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: A Meta‐Analysis
Nazmy, Ahmed , Abouelmagd, Alaa Abdrabou , Sobhy, Ahmed , Ashour, Mennatullah , El‐shirbiny, Hassan , Khalaph, Moneeb , Shaban, Ahmed Yasser , Nazmy, Mahmoud , Shabaan, Amroos , Elbanna, Abdullah Farahat, Hafez, Abdelrahman , Gibson, C. Michael

Mayo Clinic

Pacing and Clinical Electrophysiology | October 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/pace.70465 | PMID 42855979 Get It

ABSTRACT Background Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term comparative efficacy and safety of LAAO versus OAC in patients with AF. Methods We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non–procedure‐related bleeding. Random‐effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79‐1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80‐1.43). LAAO was associated with a significantly lower risk of non‐procedure‐related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52‐0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow‐up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator‐type subgroup analyses showed no significant interaction for MACE ( p = 0.67) or stroke ( p = 0.81) between contemporary predominantly‐DOAC and VKA comparator trials. Conclusions LAAO was associated with lower non‐procedure‐related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non‐inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long‐term bleeding burden of anticoagulation is clinically important.
Cerebral Embolic Protection Devices for the Prevention of Stroke in Patients Undergoing Transcatheter Aortic Valve Implantation: An Updated Meta‐Analysis of Randomized Controlled Trials
Nazmy, Ahmed , Sobhy, Ahmed , Elshahat, Ahmed , Abdelaziz, Ahmed , Makhlouf, Ebtsam, Elnemr, Amr, Hassanin, Mahmoud M. H., Atta, Karim , Shaban, Ahmed Yasser , Nazmy, Mahmoud, Abdelazeem, Basel , Mamas, Mamas , Hassanin, Mohammed Sabri, Nazmy, Mahmoud, Kharbanda, Rajesh K. , Abdelazeem, Basel , Mamas, Mamas A.

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 10, 2025 | Volume: 107 | Issue: 3 | Pages: 795-806

10.1002/ccd.70411 | PMID 41366883 Get It

ABSTRACT Stroke remains one of the most devastating complications following transcatheter aortic valve implantation (TAVI). Although cerebral embolic protection devices (CEPDs) have emerged to mitigate patients' risks, their impact on stroke risk, as well as other clinical and neurocognitive outcomes after TAVI, remains uncertain. We aimed to assess whether CEPDs alleviate stroke risks and neurocognitive outcomes after TAVI. We systematically searched MEDLINE, Scopus, Web of Science (WOS), and the Cochrane CENTRAL from inception until May 2025. We included randomized controlled trials (RCTs) that assessed the effectiveness of CEPD compared to the control group (no CEPD) in adult patients (> 18 years) undergoing TAVI. The primary endpoint was the incidence of all‐cause stroke. In contrast, the secondary endpoints included disabling stroke, systemic bleeding, transient ischemic attack (TIA), and major adverse cardiovascular and cerebrovascular events (MACCE). Additionally, we assessed neurological outcomes, including changes in the Montreal Cognitive Assessment (MoCA) score, the National Institutes of Health Stroke Scale (NIHSS) score, and the presence of new ischemic lesions. Nine RCTs comprising 11,696 patients were included in the final analysis. The use of CEPDs showed no statistical difference in reducing all‐cause stroke compared to the control group (OR = 0.91, 95% CI [0.73–1.15], p = 0.44). Additionally, there was no significant difference in other studies' secondary outcomes, including disabling stroke, MACCE, systemic bleeding, or neurological outcomes, such as worsening NISSS, decline in MoCA score, and the presence of new ischemic lesions. The use of CEPD during TAVI showed no benefit in reducing the risks of all‐cause stroke and other neurological outcomes studied.
Abstract 4373112: High-dose Aspirin is more effective than Low-dose Aspirin for Prevention of Preeclampsia in High-risk Pregnant Women: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Hassanin, Mahmoud M. H., Qenawy, Abdulrahman, Kasem, A. , Awadalla, Yasein F., Aljanadi, Raghad, Awad, Rawan Mohammed, Awad, Mohamed M. , Ghonim, Abdullah Nasser, AlSulaiman, Sultan Bander, Alotaibi, Fahad Mohsin, Gado, Mazen Ibrahem, Balbaa, Elsayed, Sobhy, Ahmed , Hafez, Abdelrahman, Hafez, Abdelrahman , Balbaa, Elsayed , Hassanin, Mohammed Sabri, Kasem, Ahmed Wahdan, Awadalla, Yasein Fadel , Awad, Rawan Mohammed, Awad, Mohammed Yousef, Hussein, Mahmoud , Alotaibi, Fahad Mohsin, Ibrahem, Mazen

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4373112 Get It

Introduction: Preeclampsia is a multisystem progressive disease of pregnancy, characterized by a new onset of hypertension (≥ 140/90 mm Hg) with proteinuria after the 20th week of gestation. There is a conflict between United States guidelines that recommend Low-dose aspirin (LDA) and United Kingdom guidelines that recommend High-dose aspirin (HDA) for the prevention of preeclampsia in high-risk pregnant women. After the latest study that recommends HDA and the absence of pairwise meta-analyses comparing two doses, we aimed to conduct a comprehensive pairwise meta-analysis to assess whether HDA is better than LDA in the prevention of preeclampsia. Methods: We conducted a systematic search on PubMed, Scopus, Cochrane Central, and Web of Science (WOS) from inception until June 2025. All randomized controlled trials (RCTs) comparing LDA and HDA in high-risk pregnant women were included. Our primary outcome was the incidence of preeclampsia (PE), while secondary outcomes were Placental abruption, Pre-term delivery, and Intrauterine Growth Restriction (IUGR). Using random-effects models, we calculated risk ratios (RR) with 95% confidence intervals (CIs). Results: A total of 8 RCTs with 1,290 patients from the United States, Canada, England, and different Asian countries were included, among whom 642 (49.8%) patients were randomized to HDA. All studies compared HDA (≥ 150 mg) and LDA (75 mg to 81 mg). Patients with LDA had a higher risk of Preeclampsia (RR: 1.71, 95% CI: 1.19 to 2.44, p<0.001) compared to HDA. There was no significant difference between the LDA and HDA regarding Placental abruption, Pre-term delivery, and IUGR. With a pooled RR with a 95% CI (1.8, [0.91 to 3.54], P = 0.09), (1.25, [0.79 to 1.97], P = 0.34), (1.5, [0.93 to 2.42], P = 0.1), respectively. Conclusion: Among high-risk pregnant women, LDA was associated with a 71% higher incidence of preeclampsia than HDA. These results support the use of HDA as a preventive medication for preeclampsia in high-risk pregnant women.
Abstract 4368914: Diagnostic Performance of AI-Assisted Coronary CT Angiography: A Systematic Review and Meta-Analysis
Hafez, Abdelrahman , Sobhy, Ahmed , Ashour, Mennatullah, Aiash, Karim, Aldemerdash, Abdulrahman, Radi, Amro Mahmoud, Elissawy, Amir, Zahrawi, Khaled, Besheya, Tawfik, Riccelli, Richard, Arora, Aman , almahmoud, dina, Jishu, Jessan, Sobhy, Ahmed, Ashour, Mennatullah, Aldemerdash, Abdulrahman, Elaraby, Ahmed R. , Arora, Ayaan, Jishu, Jessan, Toraih, Eman Ali , Aiash, Hani

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4368914 Get It

Background: Coronary computed tomography angiography (CCTA) is vital for diagnosing ischemic heart disease, yet its accuracy is affected by varying reader expertise. Artificial Intelligence (AI)-driven automated stenosis assessment offers promise for enhancing diagnostic consistency. Aim: We aim to evaluate an AI-CCTA assessment against invasive coronary angiography, invasive FFR, and expert readings. Methods: We performed a comprehensive search in Web of Science, Scopus, PubMed, Cochrane Library, and EMBASE from inception until March 2025. Two independent reviewers screened articles and extracted data on study design, patient demographics, AI methodology, stenosis thresholds, and outcomes. For statistical analysis, we constructed summary receiver operating characteristic (SROC) curves and used a bivariate random-effects model to derive pooled sensitivity, specificity, diagnostic odds ratios (DOR), and area under the curve (AUC). Forest plots were generated to visualize these metrics. Results: Our meta-analysis included 34 studies with 10,067 patients. AI-based CCTA demonstrated excellent diagnostic performance with an AUC of 0.932 for per-patient analysis. The pooled per-patient sensitivity was 0.89 (95% CI: 0.87–0.91) and specificity was 0.80 (95% CI: 0.74–0.86), with a DOR of 37.07 (95% CI: 24.57–55.92). AI validated against expert readers achieved the highest accuracy (0.94, 95% CI: 0.87-0.98). The >70% stenosis threshold demonstrated superior performance (accuracy: 0.89, specificity: 0.96) compared to the >50% threshold (accuracy: 0.86, specificity: 0.87). Per-vessel analysis showed comparable results with an AUC of 0.905. Conclusion: Our meta-analysis confirms that AI-assisted coronary CT angiography delivers high diagnostic performance for coronary stenosis detection, with strong AUC values, high sensitivity and specificity, and robust diagnostic odds ratios across both per-patient and per-vessel assessments.